Why the CRISPR patent verdict isn’t the end of the story; Nature, February 17, 2017

Heidi Ledford, Nature; 

Why the CRISPR patent verdict isn’t the end of the story

"The US Patent and Trademark Office (USPTO) issued a key verdict this week in the battle over the intellectual property rights to the potentially lucrative gene-editing technique CRISPR–Cas9.

It ruled that the Broad Institute of Harvard and MIT in Cambridge could keep its patents on using CRISPR–Cas9 in eukaryotic cells. That was a blow to the University of California in Berkeley, which had filed its own patents and had hoped to have the Broad’s thrown out."